Sustained clinical benefit of ramucirumab plus erlotinib in EGFR mutated NSCLC, irrespective of the mutation type Sustained clinical benefit of ramucirumab plus erlotinib in EGFR mutated NSCLC, irrespective of the mutation type September 2020 ESMO 2020 Read more
2022 May Editor's pick RELEVANT LITERATURE FOR YOUR DAILY PRACTICE SELECTED BY: MARIO DICATO Read more
2022 May Clinical Practice Neoadjuvant therapy superior to upfront surgery in pancreatic cancer Read more
2022 May ELCC 2022 Sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metast... Read more
2022 May ELCC 2022 Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR-mutated lung adenocarci... Read more